Breaking News Instant updates and real-time market news.

SPRO

Spero Therapeutics

$14.99

0.19 (1.28%)

, AGN

Allergan

$166.26

1.195 (0.72%)

15:34
04/12/18
04/12
15:34
04/12/18
15:34

Spero Therapeutics surges over 10% after hiring ex Allergan VP Critchley

Earlier today, Spero (SPRO) Therapeutic sannounced the appointment of Ian A. Critchley, Ph.D. as Head of Clinical Microbiology to lead Spero's pre-clinical and clinical microbiology efforts. Dr. Critchley brings over 30 years of experience in anti-infective drug discovery and development to Spero."I am pleased that Ian is joining Spero to provide leadership and expertise on microbiology for the Company," said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics. "Ian's hiring is part of our strategic plan to build the organization needed to support SPR994 in our planned Phase 3 pivotal trial and beyond, as well as to run a robust clinical portfolio. He will play an integral part in helping us achieve our mission of bringing novel therapies to market that address the growing threat of multidrug-resistant bacteria."Prior to joining Spero Therapeutics, Dr. Critchley served as Vice President of Clinical Microbiology at Allergan (AGN )since 2015, where he managed pre-clinical and clinical microbiology studies on anti-infective compounds including Teflaro(R), Avycaz, and Dalvance. Prior to Allergan, Dr. Critchley served six years at Cerexa., a subsidiary of Forest Laboratories,, as the Vice President of Clinical Microbiology overseeing microbiology studies for its anti-bacterial programs. Prior to Cerexa, Inc., Dr. Critchley served as the Executive Director of Microbiology at Replidyne, Inc. for six years and held earlier positions at Focus Technologies, Inc. and SmithKline Beecham plc. He received his Ph.D. in Microbiology from the University of Glasgow in Scotland. Shares are up over 10% in late-afternoon trading to $16.54.

SPRO

Spero Therapeutics

$14.99

0.19 (1.28%)

AGN

Allergan

$166.26

1.195 (0.72%)

  • 24

    Apr

  • 27

    Apr

  • 30

    Apr

  • 01

    May

  • 02

    May

  • 08

    May

SPRO Spero Therapeutics
$14.99

0.19 (1.28%)

11/27/17
11/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. iRadimed (IRMD) initiated with an Outperform at Credit Suisse. 2. Funko (FNKO) was initiated with a Buy at Goldman Sachs, SunTrust, BofA/Merrill, Jefferies, and Stifel, while being initiated with an Overweight at JPMorgan and an Outperform at BMO Capital. 3. Evoqua Water (AQUA) was initiated with an Outperform at RBC Capital and Raymond James, a Buy at Citi, a Hold at Stifel, as well as a Neutral at Goldman Sachs and Baird. 4. Spero Therapeutics (SPRO) was initiated with an Outperform at Oppenheimer and Cowen, a Buy at Stifel, and a Neutral at BofA/Merrill. 5. Altair (ALTR) was initiated with an Outperform at William Blair, a Buy at Deutsche Bank, a Sector Perform at RBC Capital, a Hold at Canaccord, and a Neutral at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/08/18
CANT
02/08/18
INITIATION
Target $27
CANT
Overweight
Spero Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen initiated Spero Therapeutics with an Overweight and $27 price target.
02/09/18
02/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Motorola Solutions (MSI) initiated with a Neutral at JPMorgan. 2. Spero Therapeutics (SPRO) initiated with an Overweight at Cantor Fitzgerald. 3. County Bancorp (ICBK) initiated with a Neutral at DA Davidson. 4. Diplomat Pharmacy (DPLO) initiated with a Buy at Lake Street. 5. Pulmatrix (PULM) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/03/18
CANT
04/03/18
NO CHANGE
Target $27
CANT
Overweight
Spero Therapeutics should rally as pipeline advances, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Spero Therapeutics with a $27 price target following the company's "solid" Q4 results. The analyst expects upward earnings revisions and multiple expansion as the company advances its pipeline toward commercialization.
AGN Allergan
$166.26

1.195 (0.72%)

03/14/18
RBCM
03/14/18
NO CHANGE
RBCM
Outperform
RBC says Allergan sent clear message that all strategic options being evaluated
RBC Capital analyst Randall Stanicky said that Allergan Chairman and CEO Brent Saunders and new CFO Matt Walsh sent a "clear" message while presenting earlier at an investor conference that all strategic options are being evaluated "with a sense of urgency." This message, which he said is the one he had hoped to hear, will keep the asset sale/break-up debate in the stock, said Stanicky. The analyst, who expects the Street's focus on asset sales to pick up following this, keeps an Outperform rating on Allergan shares.
03/15/18
JPMS
03/15/18
NO CHANGE
Target $265
JPMS
Overweight
Allergan CEO comments on evaluating options a 'clear positive,' says JPMorgan
JPMorgan analyst Chris Schott views Allergan CEO Brent Saunders' comments yesterday on evaluating all options to create value as a "clear positive." The company is focusing on core business execution with a set of near-term pipeline opportunities while also examining other potential value-unlocking options for the business, Schott tells investors in a research note. The analyst says he has long argued that Allergan's core business is "significantly undervalued" and that any shift toward greater Botox/aesthetics exposure would result in a company that trades at a "distinctly higher multiple" than the current business. As such, he believes selling or spinning off assets could unlock value. Schott keeps an Overweight rating on Allergan with a $265 price target.
03/26/18
WBLR
03/26/18
NO CHANGE
WBLR
Outperform
William Blair sees Biohaven safety as 'strong differentiator' versus Allergan
William Blair analyst Tim Lugo believes Biohaven Pharmaceutical's (BHVN) Phase III data this morning confirmed rimegepant's efficacy and "clean" safety profile. The analyst keeps an Outperform rating on the shares, which are trading down 29%, or $7.12, to $17.64. Lugo understands the focus on comparing today's results with the recent ubrogepant Phase III data from Allergan (AGN), but he notes that comparisons are complicated as Biohaven did not allow rescue medications or re-dosing. While the efficacy in Study 302 looked in line with Allergan's ubrogepant Phase III study, Study 301 looked to be affected by a higher placebo rate of a few percentage points, which negatively affected the difference versus placebo, Lugo tells investors in a research note. He believes safety for rimegepant is "impressive" and likely a " William Blair sees Biohaven safety as 'strong differentiator' versus AllerganWhile a drop-off in efficacy between Phase II and Phase III results is common, it may have been exacerbated as management noted the rimegepant formulation in the Phase III took 30 minutes longer to reach serum maximal concentration than the formulation used in Phase II, Lugo points out. Further, he thinks the profile of rimegepant could be boosted by the company's Phase III trial of a rapidly dissolving sublingual rimegepant formulation using Catalent's (CTLT) Zydis technology, which the analyst says should lead to a faster bioavailability.
04/12/18
DBAB
04/12/18
NO CHANGE
Target $212
DBAB
Buy
Deutsche Bank likes current setup for shares of Allergan
Allergan shares at current levels likely reflect concerns about the growth and durability of core franchises, low expectations for current pipeline assets, and skepticism about the company's ability to bolster the pipeline, Deutsche Bank analyst Gregg Gilbert tells investors in a research note. His $212 price target includes value for only four late-stage pipeline assets, each with validating events in 2018. Removing these assets would reduce his target to $183, all else equal. Not all of the programs are likely to fail, Gilbert argues. As such, he likes the setup for the stock from here in the event of positive pipeline news and strong operational performance. He keeps a Buy rating on Allergan.

TODAY'S FREE FLY STORIES

ANTM

Anthem

$238.81

13.73 (6.10%)

05:22
04/26/18
04/26
05:22
04/26/18
05:22
Upgrade
Anthem rating change  »

Anthem upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$159.69

0.03 (0.02%)

05:20
04/26/18
04/26
05:20
04/26/18
05:20
Recommendations
Facebook analyst commentary  »

Facebook price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERN

Erin Energy

$1.65

-0.825 (-33.33%)

05:18
04/26/18
04/26
05:18
04/26/18
05:18
Hot Stocks
Erin Energy files voluntary petitions under Chapter 11 to pursue reorganization »

Erin Energy and certain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTXS

Citrix

$96.54

0.04 (0.04%)

05:16
04/26/18
04/26
05:16
04/26/18
05:16
Recommendations
Citrix analyst commentary  »

Citrix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 08

    May

  • 09

    May

AMD

AMD

$9.72

-0.37 (-3.67%)

05:13
04/26/18
04/26
05:13
04/26/18
05:13
Recommendations
AMD analyst commentary  »

AMD could see…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

EBAY

eBay

$40.98

-0.2 (-0.49%)

05:09
04/26/18
04/26
05:09
04/26/18
05:09
Recommendations
eBay analyst commentary  »

eBay GMV growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRVG

Trivago

$4.71

-1.65 (-25.94%)

05:01
04/26/18
04/26
05:01
04/26/18
05:01
Downgrade
Trivago rating change  »

Trivago downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPR

HighPoint Resources

$6.65

0.14 (2.15%)

04:58
04/26/18
04/26
04:58
04/26/18
04:58
Initiation
HighPoint Resources initiated  »

HighPoint Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

AVY

Avery Dennison

$106.68

1.195 (1.13%)

04:57
04/26/18
04/26
04:57
04/26/18
04:57
Upgrade
Avery Dennison rating change  »

Avery Dennison upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Jobless Claims to be reported at 08:30 »

Week of 4/21 Jobless…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Breaking General news story  »

Week of 4/25 Fed Balance…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Durable Goods Orders to be reported at 08:30 »

March Durable Goods…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Durable Goods Orders Ex-transportation to be reported at 08:30 »

March Durable Goods…

WYN

Wyndham

$117.67

1.83 (1.58%)

, LQ

La Quinta

$19.70

0.08 (0.41%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
La Quinta to host special shareholder meeting »

Special Shareholder…

WYN

Wyndham

$117.67

1.83 (1.58%)

LQ

La Quinta

$19.70

0.08 (0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 02

    May

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Wholesale Inventories [Advance] M/M % hange to be reported at 08:30 »

March Wholesale…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
International Trade in Goods Balance to be reported at 08:30 »

March International Trade…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Breaking General news story  »

Week of 4/16 Money Supply…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Breaking General news story  »

6-Month Bill Announcement…

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Breaking General news story  »

Week of 4/20 EIA Natural…

SMMT

Summit Therapeutics

$13.66

0.13 (0.96%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
Summit Therapeutics management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

ABBV

AbbVie

$91.91

0.57 (0.62%)

, ACOR

Acorda Therapeutics

$22.95

-0.15 (-0.65%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
American Academy of Neurology to hold annual meeting »

2018 Annual Meeting of…

ABBV

AbbVie

$91.91

0.57 (0.62%)

ACOR

Acorda Therapeutics

$22.95

-0.15 (-0.65%)

ALXN

Alexion

$106.07

-0.37 (-0.35%)

AKCA

Akcea Therapeutics

$26.85

0.02 (0.07%)

RHHBY

Roche

TEVA

Teva

$17.27

-0.28 (-1.60%)

UBS

UBS

$16.78

-0.095 (-0.56%)

MDT

Medtronic

$79.47

0.12 (0.15%)

MCK

McKesson

$151.70

2.76 (1.85%)

NVTA

Invitae

$5.53

-0.15 (-2.64%)

IONS

Ionis Pharmaceuticals

$43.98

-1.35 (-2.98%)

IPXL

Impax

$19.25

-0.65 (-3.27%)

DNA

Bought by RHHBY

DGX

Quest Diagnostics

$101.17

1.42 (1.42%)

ESALY

Eisai

DEPO

Depomed

$6.66

-0.17 (-2.49%)

CPRX

Catalyst Pharmaceuticals

$2.64

0.04 (1.54%)

BSX

Boston Scientific

$29.44

1.01 (3.55%)

BMRN

BioMarin

$81.41

0.33 (0.41%)

MYL

Mylan

$38.93

-1.32 (-3.28%)

NBIX

Neurocrine

$78.13

-0.3 (-0.38%)

NVS

Novartis

$76.42

-0.58 (-0.75%)

PFE

Pfizer

$36.69

-0.36 (-0.97%)

RARX

RA Pharmaceuticals

$5.76

-0.2 (-3.36%)

SNY

Sanofi

$40.11

0.335 (0.84%)

SYK

Stryker

$165.44

0.77 (0.47%)

SUPN

Supernus

$47.30

0.55 (1.18%)

LLY

Eli Lilly

$81.17

1.08 (1.35%)

BAYRY

Bayer

AMGN

Amgen

$174.83

2.92 (1.70%)

ALNY

Alnylam

$94.35

-0.34 (-0.36%)

BIIB

Biogen

$269.47

7.45 (2.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 30

    Apr

  • 30

    Apr

  • 01

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 04

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 17

    May

  • 18

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 25

    May

  • 28

    May

  • 30

    May

  • 05

    Jun

  • 07

    Jun

  • 07

    Jun

  • 12

    Jun

  • 12

    Jun

  • 16

    Jun

  • 06

    Jul

  • 11

    Aug

  • 12

    Sep

  • 05

    Oct

  • 20

    Oct

  • 13

    Nov

  • 28

    Jan

SCPH

scPharmaceuticals

$9.92

-0.1 (-1.00%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
scPharmaceuticals management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 23

    Jun

ALNA

Allena Pharmaceuticals

$14.77

0.845 (6.07%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
Allena Pharmaceuticals management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

RIO

Rio Tinto

$55.24

-0.44 (-0.79%)

04:55
04/26/18
04/26
04:55
04/26/18
04:55
Conference/Events
Rio Tinto management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

04:55
04/26/18
04/26
04:55
04/26/18
04:55
General news
Breaking General news story  »

Week of 4/22 Bloomberg…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.